Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pembrolizumab (Primary) ; Rinatabart sesutecan (Primary)
  • Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; HER2 negative breast cancer; Male breast cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors ProfoundBio

    • Most Recent Events

    • 17 Jan 2025 Planned number of patients changed from 374 to 404.
    • 17 Jan 2025 Planned End Date changed from 1 Apr 2026 to 1 Oct 2026.
    • 17 Jan 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Apr 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top